Enanta Pharmaceuticals (9EP) AI Stock Analysis

Enanta Pharmaceuticals

(Frankfurt:9EP)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Very high gross marginA roughly 98% gross margin shows that Enanta’s offerings can generate substantial value after direct costs. If its pipeline produces commercially viable medicines or partnered products, this underlying economics could support attractive contribution margins, even though current operating expenses still exceed gross profit.

Negative Factors

Persistent operating lossesDeep operating and net losses indicate that Enanta’s current business activities do not yet cover its cost base. Sustained unprofitability can erode equity, constrain investment in research programs, and increase dependence on successful partnerships, milestones, or future external financing.

Enanta Pharmaceuticals (9EP) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 311.93M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -4.4
Beta (1Y): 1.11
Revenue Growth: -6.02%
EPS Growth: 48.10%
Country: Germany
Employees: 120
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Enanta Pharmaceuticals Business Overview & Revenue Model

Company Description

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focus...

Enanta Pharmaceuticals Earnings Call Summary

Earnings Call Date:May 05, 2024(Q2-2024)|% Change Since:-29.32%|Next Earnings Date:Nov 15, 2026

Earnings Call SentimentNeutral

The earnings call presented a mixed sentiment with significant advancements in the RSV and immunology programs and a stable financial position. However, it also highlighted challenges with a decline in revenue, increased net loss, and slower enrollment in the RSVPEDs study.

Positive Updates

RSV Program Advancements

Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.

Negative Updates

Revenue Decline

Total revenue for the quarter decreased to $17.1 million from $17.8 million in the same period in 2023, primarily due to lower royalty rates.

Company Guidance

During the earnings call for Enanta Pharmaceuticals' fiscal second quarter of 2024, the company provided guidance on several key metrics. For the quarter, total revenue was reported at $17.1 million, primarily from royalty revenue tied to AbbVie's MAVYRET sales. The company updated its expense guidance, projecting research and development expenses to range between $125 million and $145 million, reflecting increased investment in its RSV and new immunology programs. General and administrative expenses are expected to be between $50 million and $60 million, influenced by additional stock compensation and legal costs. Enanta concluded the quarter with approximately $300 million in cash and marketable securities, anticipating this will support its existing operations through the third quarter of fiscal 2027. The company is also advancing its RSV and CSU programs, with milestones including data readouts expected in the second half of 2024 and the introduction of a second immunology program.

Enanta Pharmaceuticals Risk Analysis

Enanta Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Enanta Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the detailed discussion of risk factors included in our 2025 Form 10-K.There have been no material changes to such risk factors during the three months ended June 30, 2026. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.Q2, 2026

Enanta Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9EP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALLO	50Neutral	$407.68M	-1.76	-50.04%	―	―	40.16%
TECX	46Neutral	$386.69M	-4.33	-35.26%	―	―	-13.09%
ABEO	45Neutral	$248.75M	-3.83	-41.69%	―	6280.00%	-212.54%
NMRA	38Underperform	$69.00M	-0.30	-242.28%	―	―	21.31%
JBIO	37Underperform	$894.18M	-5.11	-49.11%	―	―	91.41%

* Healthcare Sector Average

Performance Comparison

DE:9EP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9EP	Enanta Pharmaceuticals	9.40	0.25	2.73%
ABEO	Abeona Therapeutics Inc	4.35	-0.43	-9.00%
TECX	Tectonic Therapeutic Inc	19.78	2.27	12.96%
ALLO	Allogene Therapeutics	1.18	0.00	0.00%
JBIO	Jade Biosciences, Inc.	14.06	4.59	48.47%
NMRA	Neumora Therapeutics, Inc.	0.37	-2.64	-87.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Enanta Pharmaceuticals AI Stock Analysis